Patents by Inventor Joy Burchell

Joy Burchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180334507
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: June 12, 2018
    Publication date: November 22, 2018
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 10017576
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 10, 2018
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Publication number: 20160176975
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: February 10, 2016
    Publication date: June 23, 2016
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 9359436
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: June 7, 2016
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Publication number: 20150065692
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 5, 2015
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 8912311
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: December 16, 2014
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Publication number: 20140005366
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: April 16, 2013
    Publication date: January 2, 2014
    Applicants: Cancer Research Technology Limited, Københavns Universitet
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 8440798
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: May 14, 2013
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Publication number: 20100034825
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: October 4, 2007
    Publication date: February 11, 2010
    Applicants: Kobenhavns Universitet, Cancer Research Tecnology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sorensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Publication number: 20050260604
    Abstract: An expression vector is used to express a polypeptide comprising the core protein of a human polymorphic epithelial mucin, which core protein is specifically bound by monoclonal antibody. SM3. The vector may be used to elicit an immune response in a subject, and to thereby immunize that subject against a disease.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 24, 2005
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • Publication number: 20020071830
    Abstract: An expression vector is used to express a polypeptide comprising the core protein of a human polymorphic epithelial mucin, which core protein is specifically bound by monoclonal antibody. SM3. The vector may be used to elicit an immune response in a subject, and to thereby immunize that subject against a disease.
    Type: Application
    Filed: December 5, 2000
    Publication date: June 13, 2002
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • Patent number: 6222020
    Abstract: Antigens are derived from the tandem repeat sequence of the core protein of a human polymorphic epithelial mucin. These antigens include a core protein epitope which is recognized by certain antibodies which also bind certain carcinoma antigens, but not fully processed HPEM glycoprotein as produced by the normal lactating human mammary gland.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 24, 2001
    Assignee: Imperial Cancer Research Technology Limited
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • Patent number: 6054438
    Abstract: Nucleic acid fragments are described which can be used as probes for detecting one of the strands of the DNA tandem repeat sequence in the gene encoding the core protein of human polymorphic epithelial mucin, or incorporated into an expression vector to encode a portion of the mucin core protein to be used for immunization purposes.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 25, 2000
    Assignee: Imperial Cancer Research Technology Limited
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • Patent number: 5683674
    Abstract: Antibodies which bind to the core protein of the human polymorphic epithelial mucin glycoprotein are useful in the diagnosis of cancer.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Imperial Cancer Research Technology Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell